Vir Biotechnology, Inc. VIR
13.13 USD -0.02 (-0.15%)
At closeNov 11, 2026, 5:32 PM EST
13.00 -0.13 -0.99%
After hours · Nov 11, 5:32 PM ET
12.94 Day range 13.43
5.32 52-week range 14.38
- YTD
- +117.74%
- 1 year
- +129.95%
News
benzinga.com Morgan Stanley Maintains Overweight on Vir Biotechnology, Raises Price Target to $28 Morgan Stanley analyst Michelle Gilson maintains Vir Biotechnology (NASDAQ:VIR) with a Overweight and raises the price target from $25 to $28.
benzinga.com Evercore ISI Group Maintains Outperform on Vir Biotechnology, Raises Price Target to $25 Evercore ISI Group analyst Cory Kasimov maintains Vir Biotechnology (NASDAQ:VIR) with a Outperform and raises the price target from $22 to $25.
marketbeat.com Vir Biotechnology Hepatitis Delta Treatment Meets Phase III Goals, With 79% Virus-Free at Week 48 Vir Biotechnology NASDAQ: VIR said its combination treatment for chronic hepatitis delta met the primary and key secondary endpoints in the pivotal Phase III ECLIPSE 1 trial, with 79% of treated…
seekingalpha.com Vir Biotechnology: Fairly Valued After Phase 3 Success? Vir Biotechnology remains a Buy after flawless Phase 3 ECLIPSE 1 results and a major new Gilead partnership. VIR's Hepatitis Delta therapy achieved 44% primary endpoint success and 79% undetectable…
seekingalpha.com Vir Biotechnology, Inc. (VIR) Discusses ECLIPSE 1 Topline Results and Expanded SOLSTICE Data Transcript Vir Biotechnology, Inc. ( VIR ) Discusses ECLIPSE 1 Topline Results and Expanded SOLSTICE Data November 9, 2026 8:30 AM EST Company Participants Kiki Patel - Head of Investor Relations Marianne De…
investors.com Vir, A Gilead Rival, Shoots To Two-Year High On Its 'Clean Win' In Hepatitis D Treatment Vir stock catapulted to a nearly two-year high Monday on a "clean win" for its experimental hepatitis D treatment.
benzinga.com HC Wainwright & Co. Reiterates Buy on Vir Biotechnology, Maintains $22 Price Target HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Vir Biotechnology (NASDAQ:VIR) with a Buy and maintains $22 price target.
zacks.com Wall Street Analysts Predict a 75.59% Upside in Vir Biotechnology (VIR): Here's What You Should Know The mean of analysts' price targets for Vir Biotechnology (VIR) points to a 75.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement…
benzinga.com Vir Biotech Highlights Significant Viral Suppression in Advanced Liver Disease Study Vir Biotechnology reported positive Phase 3 ECLIPSE 1 data for its chronic hepatitis delta treatment ahead of planned 2027 FDA filings.
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers MaxCyte (NASDAQ:MXCT) stock increased by 21.4% to $1.53 during Monday's pre-market session. The market value of their outstanding shares is at $130.0 million. Vir Biotechnology (NASDAQ:VIR)…
benzinga.com Why Greenfire Resources Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket Greenfire shares surged 25% after Strathcona announced a C$2.7B-C$2.9B acquisition; several small-cap stocks posted sharp premarket gains and losses.- benzinga.com Reported Sunday, Vir’s Elebsiran And Tobevibart Meet Primary Endpoint In Phase 3 ECLIPSE 1 Hepatitis Delta Trial, 44% Achieve Undetectable Virus Plus ALT Normalization Versus 0% Delayed Treatment Trial met all Phase 3 endpoints and regimen is well-tolerated with all patients completing 48 weeks of treatment100% of patients achieved virologic response at Week 24 with 79% of patients reaching…
gurufocus.com Vir Biotechnology Announces Primary Endpoint Met in Pivotal Phase 3 ECLIPSE 1 Trial for Elebsiran and Tobevibart in Chronic Hepatitis Delta Vir Biotechnology, Inc. (Nasdaq: VIR), today announced positive topline results from the pivotal Phase 3 ECLIPSE 1 trial evaluating monthly subcutaneous adminis
gurufocus.com Vir Biotechnology Announces Expanded Phase 2 SOLSTICE Data for Elebsiran and Tobevibart in Chronic Hepatitis Delta, Showing Deep and Sustained Viral Suppression, and Exploratory Finite Treatment Data Vir Biotechnology, Inc. (Nasdaq: VIR), today announced new, expanded data from the Phase 2 SOLSTICE trial evaluating monthly subcutaneous administration of eleb
businesswire.com Vir Biotechnology Announces Expanded Phase 2 SOLSTICE Data for Elebsiran and Tobevibart in Chronic Hepatitis Delta, Showing Deep and Sustained Viral Suppression, and Exploratory Finite Treatment Data SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced new, expanded data from the Phase 2 SOLSTICE trial evaluating monthly subcutaneous administration of elebsiran…
businesswire.com Vir Biotechnology Announces Primary Endpoint Met in Pivotal Phase 3 ECLIPSE 1 Trial for Elebsiran and Tobevibart in Chronic Hepatitis Delta SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced positive topline results from the pivotal Phase 3 ECLIPSE 1 trial evaluating monthly subcutaneous administration…
businesswire.com Vir Biotechnology to Present Topline Phase 3 ECLIPSE 1 Data for Elebsiran and Tobevibart in Chronic Hepatitis Delta at AASLD's The Liver Meeting® 2026 and Host Investor Conference Call SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will present data from the pivotal Phase 3 ECLIPSE 1 trial evaluating the combination of elebsiran…- benzinga.com Needham Maintains Buy on Vir Biotechnology, Raises Price Target to $20 Needham analyst Joseph Stringer maintains Vir Biotechnology (NASDAQ:VIR) with a Buy and raises the price target from $18 to $20.
marketbeat.com What Vir Biotechnology (VIR) Said on Its Q3 Earnings Call Vir Biotechnology NASDAQ: VIR expects to report the first phase 3 results for its experimental hepatitis delta treatment in the fourth quarter of 2026, with data from two additional studies due in…
seekingalpha.com Vir Biotechnology, Inc. (VIR) Q3 2026 Earnings Call Transcript Vir Biotechnology, Inc. (VIR) Q3 2026 Earnings Call Transcript
zacks.com Vir Biotechnology, Inc. (VIR) Reports Q3 Loss, Misses Revenue Estimates Vir Biotechnology, Inc. (VIR) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.8. This compares to a loss of $1.17 per share a year ago.
benzinga.com Vir Biotechnology Q3 2026 Earnings Call Transcript Vir Biotechnology (NASDAQ:VIR) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…
businesswire.com Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2026 Financial Results SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported financial results for the third quarter ended September 30, 2026. “We are…
businesswire.com Vir Biotechnology to Participate in the Jefferies 2026 London Healthcare Conference SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, President and Chief Executive Officer, will present at the Jefferies…
businesswire.com Vir Biotechnology Announces Appointment of Suzanne Topalian to its Board of Directors SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced the appointment of Suzanne Topalian, M.D., to its Board of Directors, effective October 27, 2026. Dr.…
seekingalpha.com Vir Biotechnology: A Big Pharma Collaboration And 2 Clinical Catalysts This Quarter VIR's PRO-XTEN platform has attracted major pharma collaborations, validating its dual-masked T-cell engager technology for oncology and solid tumors. Near-term catalysts include ECLIPSE program…
defenseworld.net Critical Survey: REGENXBIO (NASDAQ:RGNX) versus Vir Biotechnology (NASDAQ:VIR) REGENXBIO (NASDAQ: RGNX - Get Free Report) and Vir Biotechnology (NASDAQ: VIR - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two…
zacks.com Can Gilead's Deal With VIR Boost Its Oncology Pipeline and Growth? Gilead Sciences expands its oncology pipeline through a Vir Biotechnology deal worth up to $1.74 billion in additional milestones, targeting three novel cancer therapies.
benzinga.com Vir Biotechnology, Gilead Strike Deal for Novel Tumor Treatments Vir Biotechnology Inc. (NASDAQ:VIR) announced a major collaboration with Gilead Sciences Inc. (NASDAQ:GILD) to create three novel T-cell engagers (TCEs) aimed at treating solid tumors.
benzinga.com Vir Biotechnology, Gilead Strike Deal for Novel Tumor Treatments Vir Biotechnology and Gilead collaborate on novel T-cell engagers for solid tumors in a deal worth up to $1.87 billion, plus royalties.
benzinga.com Vir Biotechnology Signs Up To $1.875B Gilead Deal For 3 Cancer Drug Candidates; Gilead To Pay $65M Cash Upfront And Buy 1,765,486 Shares At $14.16 Each, For A Total Of $25M, Plus Up To $1.785B In Milestones And Royalties Under the terms of the agreement, Vir Biotechnology will be responsible for discovery, design and optimization of three novel PRO-XTEN® dual-masked TCE development candidates targeting selected solid…- benzinga.com Vir Biotechnology Announces Collaboration, License Agreement With Gilead To Discover, Engineer Three PRO-XTEN Dual-Masked T-Cell Engager Development Candidates Targeting Selected Solid Tumor-Associated Antigens - Collaboration combines Vir Biotechnology’s T-cell engager discovery, AI-enabled protein engineering and clinically-validated PRO-XTEN® masking technology with Gilead’s oncology development and…
benzinga.com Vir Biotechnology Receives FDA Fast Track Designation For VIR-5500 To Treat Metastatic Castration-Resistant Prostate Cancer Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to VIR-5500, a PSMA-targeted PRO-XTEN® dual-masked T-cell engager…
benzinga.com HC Wainwright & Co. Maintains Buy on Vir Biotechnology, Raises Price Target to $22 HC Wainwright & Co. analyst Patrick R. Trucchio maintains Vir Biotechnology (NASDAQ:VIR) with a Buy and raises the price target from $20 to $22.
benzinga.com Vir Biotechnology To Reveal Expanded Phase 2 SOLSTICE Results for Elebsiran And Tobevibart In Hepatitis Delta at AASLD’s The Liver Meeting 2026 Vir Biotechnology, Inc. (NASDAQ:VIR) today announced the Company will present data from the Phase 2 SOLSTICE trial evaluating the combination of elebsiran and tobevibart for chronic hepatitis delta…- benzinga.com Vir Biotechnology Appoints Aziz Sawaf CFO, Effective Oct. 5 Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Aziz Sawaf, MBEE, MBA, CFA, as Executive Vice President and Chief Financial Officer (CFO), effective October 5, 2026. Mr.…
benzinga.com Vir Biotechnology Q2 EPS $0.47 Beats $0.18 Estimate, Sales $238.946M Beat $216.456M Estimate Vir Biotechnology (NASDAQ:VIR) reported quarterly earnings of $0.47 per share which beat the analyst consensus estimate of $0.18 by 161.11 percent. This is a 158.75 percent increase over losses of…- benzinga.com Morgan Stanley Maintains Overweight on Vir Biotechnology, Raises Price Target to $27 Morgan Stanley analyst Michelle Gilson maintains Vir Biotechnology (NASDAQ:VIR) with a Overweight and raises the price target from $23 to $27.
- benzinga.com Leerink Partners Maintains Outperform on Vir Biotechnology, Raises Price Target to $21 Leerink Partners analyst Roanna Ruiz maintains Vir Biotechnology (NASDAQ:VIR) with a Outperform and raises the price target from $20 to $21.
- benzinga.com Vir Biotechnology To Present Data From Its Phase 2 SOLSTICE Study Of Obevibart And Elebsiran Combination To Treat Chronic Hepatitis Delta Vir Biotechnology, Inc. (NASDAQ:VIR) today announced the Company will present data from the Phase 2 SOLSTICE trial evaluating the combination of tobevibart and elebsiran for chronic hepatitis delta…
benzinga.com Earnings Scheduled For May 6, 2026 - benzinga.com Vir Biotechnology Q1 2026 GAAP EPS $(0.85) Up From $(0.88) YoY, Sales $(29.000K) Down From $3.032M YoY. Vir Biotechnology (NASDAQ:VIR) reported quarterly losses of $(0.85) per share. This is a 3.41 percent increase over losses of $(0.88) per share from the same period last year. The company reported…
- benzinga.com Vir Biotech Doses First Patient In Phase 1 Expansion Trial Of VIR-5500 For Metastatic Prostate Cancer Phase 1 trial designed to assess the safety, pharmacokinetics and preliminary efficacy of VIR-5500 in both early and late-line metastatic castration-resistant prostate cancer (mCRPC) and metastatic…
benzinga.com Semtech To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Wednesday Wall Street analysts changed outlook on top names. For full view of changes, including upgrades/downgrades, see analyst ratings page.
benzinga.com HC Wainwright & Co. Maintains Buy on Vir Biotechnology, Raises Price Target to $20 HC Wainwright & Co. analyst Patrick R. Trucchio maintains Vir Biotechnology (NASDAQ:VIR) with a Buy and raises the price target from $15 to $20.
benzinga.com C3.ai Posts Downbeat Results, Joins Trade Desk, FTAI Aviation And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
benzinga.com Why Marriott Vacations Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket - benzinga.com Barclays Maintains Overweight on Vir Biotechnology, Raises Price Target to $30 Barclays analyst Etzer Darout maintains Vir Biotechnology (NASDAQ:VIR) with a Overweight and raises the price target from $26 to $30.
- benzinga.com Vir Biotechnology Commences $200M Common Stock Offering Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious…